Modern immunosuppressives

Modern immunosuppressives

by Jean-François Bach

Browse books you can read free on Readfeed

No club is reading this yet — be the first to start one

Start a club free
About
"Expanding from the classic use of immunosuppressants in transplantation and rejection, this current overview highlights their new roles in clinical medicine. Immunosuppressants are at the forefront of new treatment modalities. Individual chapters focus on their use not only in prevention or treatment of transplant rejection, but also on their use in immune-complex and autoimmune diseases, including rheumatoid arthritis; on combination therapies to achieve synergy in immunosuppression; on new drugs, low molecular weight chemicals, the use of antibodies and gene therapy; on immunological tolerance to prevent or inhibit transplant rejection; and how data derived from transplant studies can be applied to other avenues of immunosuppression." "Clinicians and researchers will appreciate the scope of the work and the presentation of new approaches in the rapidly developing field of immunosuppression."--BOOK JACKET.

Discuss Modern immunosuppressives with other readers

Join or start a book club for Modern immunosuppressives on Readfeed. Live chat, shared reading progress, and AI discussion questions — free to get started.

Frequently asked questions

How do I join a book club for Modern immunosuppressives?

Sign up free on Readfeed, then browse public clubs or start your own club with Modern immunosuppressives as the current read. Invite friends with a share link and discuss together with live chat and AI discussion questions.

Can I discuss Modern immunosuppressives with other readers online?

Yes. Readfeed book clubs let you chat live, share progress, and join discussions about Modern immunosuppressives with readers worldwide — whether your club is virtual, in-person, or hybrid.

Is Readfeed free?

Yes. Creating an account and joining book clubs is free. Sign up to find readers who love the same books and start discussing today.